We reported a rare extraskeletal localization of undifferentiated chondroscarcoma in a 71-year old patient. The neoplasm with a 20-year history in the left supraclavicular region exhibited a rapid growth in only a few months. Six months after a total tumor excision the patient has been in an excellent general health condition, with no signs of either a local relapse or distant metastases.
CASE REPORT
A 71-year old male patient was admitted to the Chest Surgery Department of the Institute for Pulmonary Diseases in Sremska Kamenica due to the tumor in the left supraclavicular region. The tumor had had a 20-year long history but it exhibited an exceptionally rapid growth a few months prior to admission. Before it started its intensive growth, the tumor was soft, a few centimeters in diameter, producing no troubles to the patient.
On admission, the patient was in a good general condition, lacking any subjective symp- Regarding the established tumor type, the consulting oncologist abandoned both the irradiation and chemotherapy treatment. On the control examination six months later, the patient was in an excellent general health condition, free of symptoms (Figure 4 ).
The radiological finding showed signs of the surgery-induced left phrenic nerve paresis, but no local relapse or distant metastases.
DISCUSSION
Chondrosarcoma is resistant to both irradiation and chemotherapy (5), so a radical largescale surgical resection is the therapy of choice regardless the tumor localization. However, the surgical treatment is usually ineffective due to a local relapse of the tumor, occurring in 50% of the patients (6) . Although the benefits from chemotherapy have not been confirmed yet, it is sometimes applied for high malignancy tumors with distant metastases.
Chondrosarcoma makes 5%-10% of all neck and head tumors (7). Due to the low incidence rate of regional lymph node metastases (8%-10%), the neck dissection is not necessary, except when lymphadenomegally of the neck lymph nodes is present (8) .
The prognosis depends on the tumor localization and its malignancy grade. The overall 5-and 10-year survival rates are 80% and 70% respectively. Malignancy grade III and undifferentiated tumors are exceptionally aggressive, with a higher incidence of local relapses and distant metastases. Grade III tumors have the 5-year survival rate of 50% (9) . The extraskeletal localization features mesenchymal chondrosarcoma which was for the first time described as I unique pathological entity in 1956 by Lichtenstein and Bernstein (10).
These tumors make less than 2% of all chondrosarcoma cases (11), having the highest incidence in the 20-30 yr age group and the 5-year survival of about 50% (12, 13) . The extraskeletal localization of undifferentiated chondrosarcoma is very rare. Undifferentiated chondrosarcoma has a very low survival rate. Since metastases can develop long after the initial surgery, these tumors should be followed-up much longer than five years (14, 15) .
Most of the patients die within the first two postoperative years, due to a rapid metastatic dissemination of the tumor. The 5-year survival rate with this tumor type is less than 10%.
